Marcia Angell, M.D.
April 20, 1939 |
|Occupation||Physician and author|
Marcia Angell (//; born April 20, 1939) is an American physician, author, and the first woman to serve as editor-in-chief of the New England Journal of Medicine. She is currently a Senior Lecturer in the Department of Global Health and Social Medicine at Harvard Medical School in Boston, Massachusetts.
- 1 Biography
- 2 New England Journal of Medicine tenure
- 3 Positions
- 4 Awards and honors
- 5 Works
- 6 References
- 7 External links
After completing undergraduate studies in chemistry and mathematics at James Madison University in Harrisonburg, Virginia, Angell spent a year as a Fulbright Scholar studying microbiology in Frankfurt, Germany. After receiving her M.D. from Boston University School of Medicine in 1967, Angell trained in both internal medicine and anatomic pathology and is a board-certified pathologist.
Angell is a frequent contributor to both medical journals and the popular media on a wide range of topics, particularly medical ethics, health policy, the nature of medical evidence, the interface of medicine and the law, and end-of-life healthcare. Her book, Science on Trial: The Clash of Medical Evidence and the Law in the Breast Implant Case (1996) received critical acclaim. With Stanley Robbins and, later, Vinay Kumar, she coauthored the first three editions of the textbook Basic Pathology. She has written chapters in several books dealing with ethical issues in medicine and healthcare.
Angell is a member of the Association of American Physicians, the Institute of Medicine of the National Academy of Sciences, the Alpha Omega Alpha National Honor Medical Society, and is a Master of the American College of Physicians. She is also a fellow of the Committee for the Scientific Investigation of Claims of the Paranormal and is an outspoken critic of medical quackery and the promotion of alternative medicine.
New England Journal of Medicine tenure
Angell joined the editorial staff of The New England Journal of Medicine (NEJM) in 1979. She became Executive Editor in 1988, and served as interim Editor-in-Chief from 1999 until June 2000. The NEJM is the oldest continuously published medical journal, and one of the most prestigious; Angell is the first woman to have served as Editor-in-Chief of the journal since it was founded in 1812.
In 1999, Jerome P. Kassirer, M.D. resigned as NEJM's Editor-in-Chief following a dispute with the journal's publisher, the Massachusetts Medical Society, over the Society's plan to use the journal's name to brand and market other sources of healthcare information. Angell agreed to serve as interim Editor-in-Chief until a permanent editor would be chosen. She reached an agreement with the society that the Editor-in-Chief would have authority over usage of the journal's name and logo, and that the journal's name would not be used on other products. Angell was a finalist for the permanent post of Editor-in-Chief, but withdrew as a candidate explaining she was retiring to write a book on alternative medicine. Angell retired from the journal in June 2000 and was replaced by Jeffrey Drazen, M.D.
Critic of conflicts of interest and biases in the medical establishment
...Similar conflicts of interest and biases exist in virtually every field of medicine, particularly those that rely heavily on drugs or devices. It is simply no longer possible to believe much of the clinical research that is published, or to rely on the judgment of trusted physicians or authoritative medical guidelines. I take no pleasure in this conclusion, which I reached slowly and reluctantly over my two decades as an editor of The New England Journal of Medicine .
Critic of the Food and Drug Administration
Commenting on the 1992 Prescription Drug User Fee Act which allowed the Food and Drug Administration (FDA) to collect fees from drug manufacturers to fund the new drug approval process, Angell has stated :
It's time to take the Food and Drug Administration back from the drug companies...In effect, the user fee act put the FDA on the payroll of the industry it regulates. Last year, the fees came to about $300 million, which the companies recoup many times over by getting their drugs to market faster.
Critic of U.S. healthcare system
Angell has long been a critic of the U.S. healthcare system. The American healthcare system is in serious crisis, she stated in a PBS special: "If we had set out to design the worst system that we could imagine, we couldn't have imagined one as bad as we have." In the PBS interview, she urges the nation to scrap its failing healthcare system and start over:
Our health care system is based on the premise that health care is a commodity like VCRs or computers and that it should be distributed according to the ability to pay in the same way that consumer goods are. That's not what health care should be. Health care is a need; it's not a commodity, and it should be distributed according to need. If you're very sick, you should have a lot of it. If you're not sick, you shouldn't have a lot of it. But this should be seen as a personal, individual need, not as a commodity to be distributed like other marketplace commodities. That is a fundamental mistake in the way this country, and only this country, looks at health care. And that market ideology is what has made the health care system so dreadful, so bad at what it does.
Critic of the pharmaceutical industry
Angell is a critic of the pharmaceutical industry. With Arnold S. Relman, she argues, "The few drugs that are truly innovative have usually been based on taxpayer-supported research done in nonprofit academic medical centers or at the National Institutes of Health. In fact, many drugs now sold by drug companies were licensed to them by academic medical centers or small biotechnology companies." The pharmaceutical industry estimates that each new drug costs them $800 million to develop and bring to market, but Angell and Relman estimate the cost to them is actually closer to $100 million. Angell is the author of The Truth About the Drug Companies: How They Deceive Us and What to Do About It.
Angell's position has been challenged by Benjamin Zycher, former senior fellow at the Manhattan Institute, who argues that although research funded by the government produces excellent basic science and even early (and unusable) versions of drugs, private investment and industrial skills are needed to produce practical products. For instance, developing mass production methods (for erythropoietin), and developing drugs without limiting adverse effects (for antidepressive drugs), selecting which drugs to test in clinical trials, and funded the clinical trials, are most commonly done by industry - not in basic research labs funded by the government. 
The combined profits for the ten drug companies in the Fortune 500 ($35.9 billion) were more than the profits for all the other 490 businesses put together ($33.7 billion) [in 2002]... Over the past two decades the pharmaceutical industry has moved very far from its original high purpose of discovering and producing useful new drugs. Now primarily a marketing machine to sell drugs of dubious benefit, this industry uses its wealth and power to co-opt every institution that might stand in its way, including the US Congress, the FDA, academic medical centers, and the medical profession itself. (Most of its marketing efforts are focused on influencing doctors, since they must write the prescriptions.) If prescription drugs were like ordinary consumer goods, all this might not matter very much. But drugs are different. People depend on them for their health and even their lives. In the words of Senator Debbie Stabenow (D-Mich.), “It’s not like buying a car or tennis shoes or peanut butter.” People need to know that there are some checks and balances on this industry, so that its quest for profits doesn’t push every other consideration aside. But there aren’t such checks and balances.
Richard Friedman, director of the psychopharmacology clinic at Weill Cornell Medical College, and a regular contributor to the New York Times science pages, criticized Angell's views as unbalanced. "Dr. Angell is now doing pretty much the same thing the industry she assails has done, just the converse. Pharma withheld the bad news about its drugs and touted the positive results; Dr. Angell ignores positive data that conflicts with her cherished theory and reports the negative results.”
Thoughts on alternative medicine
Marcia Angell is also a critic of the current categorization of alternative medicine. In a 1998 NEJM editorial she wrote with Jerome Kassirer, they argued:
- It is time for the scientific community to stop giving alternative medicine a free ride... There cannot be two kinds of medicine — conventional and alternative. There is only medicine that has been adequately tested and medicine that has not, medicine that works and medicine that may or may not work. Once a treatment has been tested rigorously, it no longer matters whether it was considered alternative at the outset. If it is found to be reasonably safe and effective, it will be accepted.
Awards and honors
- Basic Pathology 1st edition (1971, Robbins, Stanley Leonard; Angell, Marcia); 2nd ed. (1973, Robbins, S.L.; Angell, M.); 3rd ed. (1981, Robbins, S.L.; Angell, M. Kumar, Vinay)
- Science on Trial: The Clash of Medical Evidence and the Law in the Breast Implant Case. Norton. 1996. ISBN 9780393039733.
- The Truth About the Drug Companies: How They Deceive Us and What to Do About It. Random. 2004. ISBN 9780375508462.
- Biographical Sketch of Marcia Angell, M.D., F.A.C.P at the Harvard Health Caucus. Accessed September 10, 2006.
- "Harvard Medical School Department of Global Health and Social Medicine, Faculty Research Interests 2012-13" (PDF). Retrieved Jan 8, 2013.
- "Biography: Dr. Marcia Angell". National Library of Medicine. Retrieved Jan 8, 2013.
- "About NEJM Past and Present". New England Journal of Medicine. Retrieved Jan 7, 2013.
- Hoey J (September 1999). "When journals are branded, editors get burnt: the ousting of Jerome Kassirer from the New England Journal of Medicine". CMAJ 161 (5): 529–30. PMC 1230583. PMID 10497610.
- Scott Gottlieb (May 20, 2000). Controversy over new editor at New England Journal of Medicine page 1 .BMJ. Retrieved August 28, 2013.
- Marcia Angell (January 15, 2009). Drug Companies & Doctors: A Story of Corruption . The New York Review of Books. Retrieved August 28, 2013.
- Marcia Angell (February 26, 2007) Taking back the FDA . Boston.com. Retrieved August 28, 2013.
- Marcia Angell, "Are we in a health care crisis?" on PBS. Accessed September 10, 2006.
- Zycher, Benjamin (28 June 2008). "Drug Development Needs Private Industry". Wall Street Journal.
- Marcia Angell (July 15, 2004). The Truth About the Drug Companies . The New York Review of Books. Retrieved August 28, 2013.
- "A Drumbeat on Profit Takers - NYTimes.com".
- Angell M, Kassirer JP (September 1998). "Alternative medicine—the risks of untested and unregulated remedies". N. Engl. J. Med. 339 (12): 839–41. doi:10.1056/NEJM199809173391210. PMID 9738094.
- "TIME's 25 Most Influential Americans". Time. 21 April 1997.
- Angell, Marcia (2 November 2007). The Truth About Drug Companies (Video, 52 min.). Health Sciences Learning Center, University of Wisconsin-Madison.
- "Interview: Marcia Angell". The Alternative Fix. Frontline, PBS. 4 November 2003.
- Olson, Walter (11 November 1996). "Review of Marcia Angell, Science on Trial". National Review.
- "Interview: Marcia Angell". The Other Drug War. Frontline, PBS. 19 June 2003.
- Quotes by Marcia Angell
- Angell article archive from The New York Review of Books
- Roberts, Russ (November 26, 2012). "Angell on Big Pharma". EconTalk. Library of Economics and Liberty.